"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

A study has uncovered novel ancestry-specific genetic variants linked to multiple sclerosis (MS), offering new insights that ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...